

Alegranije II), <mark>wijosio</mark>ni,

- Programming and - professional Const. II. approximate and a supplementary and a supp

wyy daikow,

ra ser a de constituir de la compart de la c

ajot ira kiljenas yan. Tada (Fili yinga) mi nirahajaksi mi din indangang distrat inadding bada kadag, kan orphysiology works have been alto suppressed Constantinus from old Seasible for the quantum sealor size. • 1982.

arik ip apprinten 30 pf dilli (Lidling Shigalitert and Maleturi Acquiermeda) Regulations. , a argey of and armeal: of line indicating the color basels for the quarter enabel little block take along <u>The Circular region report legism. By Michigan Sadding Pije. It of March it Americans.</u> Charles at

icanal Massing accommensation; it is an people accident of the 15 and

ya nyakamendakan ji paraka ana sanake ana kata a

: Terricit - Italia | Extrementa | Romali,



Off: +91-40-6661 7089 +91-40-4240 8813 Mobile : 98480 18791

98491 35573

Limited Review Report

To The Board of Directors M/s. Gayatri Tissue and Papers Limited.

We have reviewed the accompanying statement of unaudited financial results of M/s. Gayatri Tissue and Papers Limited for the period ended 30.06.2021. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical primarily to inquiries of company personnel and analytical primarily to inquiries.

Painted was that the conditional and theory, and the continue of the continue

May 54: 63 Meyer Wi Arecandlythys Chartenaej Açacendepite Pangja Wygitylygitan Kapaging, 1836/84/4

> (d. Newsprosyn Mari) Persog Mariothe in Nazziwal

Pleas Nucleocal Date: 1800-2021 J.54 2500725586259202

g proposite of growing and an object of the second proposition of the

11 jda 2014 Gryss Sasudio - Robel Zabes, 1 julydyss 12 juganiaida - 1540 cets | 1,30c, 8-42-47|, 14-5 | Medinal! * Gárácki, 1765-aki vilmál, | Phys<u>| 1</u>3-49-cg. | Nicklembet - 5/63 (10-6



GAYATRI TISSUE & PAPERS LIMITED

Regd. Office:16/137 Siddharthanagar,Road No.5,Near Prabodhan Krida Bhavan, Goregaon(West), MUMBAI-400 104
UN AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2021

CIN: L45100MH1987PLC042141

Rs. In Lakhs

| | CIN: L45100MH1987PLC04 | 12141 | | | | Rs. In Lakhs |
|-----------------------------|----------------------------------------------------------------------------------|-------|-------------------------------------------|-----------------------------------------------|----------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S.No. | Particulars | | Quarter ended 30.06.2021 Un Audited | Preceding quarter 31.03.2021 Audited | Quarter ended 30.06.2020 Un Audited | Year Ended 31.03.2021 Audited |
| | | | | | | |
| (a) Revenue from operations | | 10.01 | 5.03 | 10.06 | 34.79 | |
| (b) Other Income | | | 0.07 | | 0.07 | |
| To tal Revenue (1) | | 10.01 | 5.10 | 10.06 | 34.86 | |
| 2 | Ex penses: | | | | | |
| | (a) Cost of Materials Consumed | | - | C 4 10 12 | n | . 5.02 |
| | (b) Purchase of stock-in-trade | | 12 1 10 | | | - 3 |
| | (c) Change in Inventories of finished goods, work-in-progress and stock-in-trade | | 1.50 | (2.50) | 2.50 | 2.83 |
| | (d) Employees benefits expense | | 3.16 | 3.15 | 3.16 | 12.62 |
| | (e) Finance costs | | S. E.S. | 950 | | - |
| | (f) Depreciation and amortisation expenses | | | er and | | |
| | (g) Manufacturing expenses | | - | | 2.8.0 | 18° |
| | (h) Research & Development expenses | | - | | y - 1 . | |
| | (i) Other Expenses | | 4.75 | 2.99 | 4.07 | 11.07 |
| | Total Expenses (2) | | 9.41 | 3.64 | 9.73 | 31.54 |
| 3 | Profit /Loss before exceptional and extraordinary items and tax (1-2) | | 0.60 | 1.46 | 0.33 | 3.32 |
| 4 | Exceptional Items | | | | 18 | E. |
| 5 | Profit before extraordinary items and tax (3-4) | | 0.60 | 1.46 | 0.33 | 3.32 |
| 6 | Extraordinary Items | | • | 1 11 20 | | The section of the se |
| 7 | Profit before tax (5-6) | | 0.60 | 1.46 | 0.33 | 3.32 |
| | Ta× Expenses: | | | | Sug | × " |
| | (1). Current tax | - | 0.16 | 0.37 | 0.09 | 0.86 |
| | (2). Deferred tax | | | | | |
| 9. | Profit (Loss) for the period from continuing operations (7-8) | - 1 | 0.44 | 1.09 | 0.24 | 2.46 |
| 10 | Profit / Loss from discontinuing operations | | 9€3 | 750 | - | 9 UR. |
| 11 | Tax expenses of discontinuing operations | 1 | · | - 2 | - | 1- |
| 12 | Profit/Loss from discontinuing operations (after tax) (10-11) | | s a e j | - P-1 | 11 4 5 9 | 8 H 128 128 |
| 13 | Profit (Loss) for the period (9+12) | e | 0.44 | 1.09 | 0.24 | 2.46 |
| 14 | Other Comprehensive Income | - 1 | | 47 | | |
| | A (1). Items that will not be reclassified to profit or loss | | :- | 1,2 | · - | |
| | (2). Incometax relating to items that will not be reclassified to profit or loss | | ne | 50 N (E) | | |
| | B (1). Items that will be reclassified to profit or loss | - 1 | 18 | | A Professional | X WHITE DO. 22 |
| | (2). Incometax relating to items that will be reclassified to profit or loss | | ~ ~ | | - | - |
| | Total other Comprehensive Income (A+B) | 1 | i e · | - | * | 2 |
| 15 | Total Comprehensive Income for the period (13+14) | - 1 | 0.44 | 1.09 | 0.24 | 2.46 |
| | (comprising Profit/Loss) and other comprehensive income for the period | | | | | |
| | Paid Up Equity Capital (Face value of Rs.10/- each) | | 150.00 | 150.00 | 150.00 | 150.00 |
| 17 | Reserves | | | | | 268.04 |
| 18 | Earning Per Equity Share (EPS): | | a | men K mag | | |
| | Basic and Diluted | | 0.03 | 0.07 | 0.02 | 0.16 |

Notes:

- The above results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 13th August, 2021 and the statutory auditors of the company have carried out limited review of the same.
- 2 The Company is not having any Subsidiary, Joint Ventrue and Associate, hence no consolidated results are published.
- The company does not have more than one reportable segment. Accordingly, pursuant to (IND AS 108) on segment reporting issued by the Institute of Chartered Accountants of India, segment information is not required to be provided.
- 4 There are no investor complaints pending at the beginning and end of the quarter. The company did not receive any investor compalints during the quarter.
- Previous year / quarter figures have been re-grouped and recasted wherever necessary.

Place: Hyderabad. Date: 13.08.2021 (P. MARUTHI BABU) Executive Director